EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, MOLN: Molecular Partners Ag ADR

06 Nov 25 17:20
LAST:

4.680

CHANGE:
 0.65		OPEN:
4.320		HIGH:
4.750		ASK:
0.000		VOLUME:
5.6K
CHG(%):
16.24		PREV:
4.026		LOW:
4.320		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
06 Nov 254.3204.7504.3204.6805.6K
05 Nov 254.0204.2103.9804.0269.5K
04 Nov 254.1104.2603.7203.91022.1K
03 Nov 253.9804.7203.8004.08580.7K
31 Oct 253.7403.7403.6343.634700
30 Oct 253.7703.7703.7703.7701.2K
28 Oct 253.7703.7703.7503.750300
27 Oct 253.5303.6503.5303.5901.5K
24 Oct 253.6003.6003.5403.5401.4K
23 Oct 253.7403.7403.5603.5604.1K

COMPANY PROFILE

Name:Molecular Partners Ag ADR
About:Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Sector:Healthcare
Industry:Biotechnology
Address:Wagistrasse 14, Schlieren, Switzerland, 8952
Website:https://www.molecularpartners.com
CIK:0001745114
ISIN:US60853G1067
FIGI:BBG010B7DHZ0

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:1.71 
Forward P/E:-2.22 
PEG Ratio:0.08 
Price to Sales:24.90 
Price to Book:1.54 
Operating Margin:-10.87 
Return on Assets:-0.27 
Return on Equity:-0.51 
EPS Ratio:-2.25 
Revenue:6.16M 
Shares:37.39M 
Market Cap:175.0M 

TECHNICAL INDICATORS

MA5:4.0715.1%
MA10:3.8521.4%
MA20:3.8322.3%
MA50:3.7724.2%
MA100:3.7325.4%
MA200:4.0715.0%
STO9:94.21 
STO14:94.21 
RSI14:69.31 
MTM14:0.83
ROC14:0.22 
ATR:0.29 
Week High:4.751.5%
Week Low:3.6328.8%
Month High:4.751.5%
Month Low:3.5315.0%
Year High:6.2433.3%
Year Low:3.3639.3%
Volatility:19.41